Open AccessPage kidney complicating kidney biopsy after stopping Apixaban: A physician's dilemma
Author(s) -
Macaulay Onuigbo,
Vivek Sharma,
Oluwanifemi Balogun,
Allina Ghimire
Publication year - 2020
Publication title -
indian journal of nephrology/indian journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 24
eISSN - 1998-3662
pISSN - 0971-4065
DOI - 10.4103/ijn.ijn_269_19
Subject(s) - medicine , apixaban , acute kidney injury , rivaroxaban , kidney , warfarin , dabigatran , angiomyolipoma , atrial fibrillation , kidney disease , biopsy , surgery
Page kidney was described by Page, following very elaborate experiments with animal kidneys in 1939, with persistent arterial hypertension from "cellophane perinephritis." Subsequently, it was reported after trauma, from renal cysts and tumors, and from intrarenal hematoma complicating percutaneous kidney biopsy. We describe Page kidney associated with acute kidney injury 26 days after an uncomplicated ultrasound-guided right native kidney biopsy. Patient was on Apixaban, a non-vitamin K antagonist oral anticoagulant (NOAC) for atrial fibrillation which was withheld 3 days before the procedure. It was restarted 3 days after. The evidence-base supporting guidelines and recommendations for the peri-procedural management of the NOACs is inadequate, sparse, and often conflicted. More research is warranted.